MeVis Medical Solutions AG (M3V) - Cash Flow Conversion Efficiency

Latest as of September 2023: 0.005x

Based on the latest financial reports, MeVis Medical Solutions AG (M3V) has a cash flow conversion efficiency ratio of 0.005x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€96.63K ≈ $112.97K USD) by net assets (€17.83 Million ≈ $20.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

MeVis Medical Solutions AG - Cash Flow Conversion Efficiency Trend (2006–2025)

This chart illustrates how MeVis Medical Solutions AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read M3V total debt and obligations for a breakdown of total debt and financial obligations.

MeVis Medical Solutions AG Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of MeVis Medical Solutions AG ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Texas Community Bancshares Inc
NASDAQ:TCBS
0.030x
Loyal Metals Ltd
AU:LLM
-0.034x
HCT Co. Ltd
KQ:072990
0.186x
CarParts.Com Inc
NASDAQ:PRTS
-0.100x
Lithium South Development Corp
V:LIS
-0.029x
Casing Macron Technology Co Ltd
TWO:3325
0.000x
Walkabout Resources Ltd
AU:WKT
-0.073x
Fangdd Network Group Ltd
NASDAQ:DUO
-0.071x

Annual Cash Flow Conversion Efficiency for MeVis Medical Solutions AG (2006–2025)

The table below shows the annual cash flow conversion efficiency of MeVis Medical Solutions AG from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see MeVis Medical Solutions AG market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-09-30 €17.83 Million
≈ $20.84 Million
€3.88 Million
≈ $4.54 Million
0.218x +23.29%
2024-09-30 €17.83 Million
≈ $20.84 Million
€3.15 Million
≈ $3.68 Million
0.177x -46.25%
2023-09-30 €17.83 Million
≈ $20.84 Million
€5.85 Million
≈ $6.84 Million
0.328x +20.52%
2022-09-30 €17.83 Million
≈ $20.84 Million
€4.86 Million
≈ $5.68 Million
0.272x -46.80%
2021-09-30 €17.83 Million
≈ $20.84 Million
€9.13 Million
≈ $10.68 Million
0.512x +215.97%
2020-09-30 €17.83 Million
≈ $20.84 Million
€2.89 Million
≈ $3.38 Million
0.162x -55.84%
2019-09-30 €17.83 Million
≈ $20.84 Million
€6.54 Million
≈ $7.65 Million
0.367x +113.19%
2018-09-30 €32.06 Million
≈ $37.48 Million
€5.52 Million
≈ $6.45 Million
0.172x -23.55%
2017-09-30 €32.51 Million
≈ $38.01 Million
€7.32 Million
≈ $8.56 Million
0.225x +111.15%
2016-09-30 €32.89 Million
≈ $38.45 Million
€3.51 Million
≈ $4.10 Million
0.107x -45.32%
2015-09-30 €33.73 Million
≈ $39.43 Million
€6.58 Million
≈ $7.69 Million
0.195x +22.25%
2014-09-30 €30.27 Million
≈ $35.39 Million
€4.83 Million
≈ $5.65 Million
0.160x -43.60%
2013-09-30 €26.45 Million
≈ $30.92 Million
€7.48 Million
≈ $8.75 Million
0.283x +21.84%
2012-09-30 €22.77 Million
≈ $26.62 Million
€5.29 Million
≈ $6.18 Million
0.232x -5.73%
2011-09-30 €20.73 Million
≈ $24.23 Million
€5.11 Million
≈ $5.97 Million
0.246x +23.38%
2010-09-30 €24.79 Million
≈ $28.98 Million
€4.95 Million
≈ $5.79 Million
0.200x +112.02%
2009-09-30 €32.61 Million
≈ $38.12 Million
€3.07 Million
≈ $3.59 Million
0.094x +5.62%
2008-09-30 €32.61 Million
≈ $38.13 Million
€2.91 Million
≈ $3.40 Million
0.089x +211.17%
2007-09-30 €30.77 Million
≈ $35.97 Million
€-2.47 Million
≈ $-2.89 Million
-0.080x -104.63%
2006-09-30 €2.65 Million
≈ $3.10 Million
€4.59 Million
≈ $5.37 Million
1.732x --

About MeVis Medical Solutions AG

XETRA:M3V Germany Health Information Services
Market Cap
$49.79 Million
€42.59 Million EUR
Market Cap Rank
#22273 Global
#1963 in Germany
Share Price
€23.40
Change (1 day)
+0.00%
52-Week Range
€22.20 - €26.40
All Time High
€35.79
About

MeVis Medical Solutions AG develops software for recording, analyzing, and evaluating image data to manufacturers of medical devices, providers of medical IT platforms, and clinical end customers in the United States and Europe. The company provides image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, liver, and neurological diseases. It also of… Read more